Public Sector Pension Investment Board Buys 6,400 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Public Sector Pension Investment Board raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 54,122 shares of the biopharmaceutical company’s stock after purchasing an additional 6,400 shares during the period. Public Sector Pension Investment Board’s holdings in Gilead Sciences were worth $4,538,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cetera Investment Advisers boosted its stake in shares of Gilead Sciences by 127.6% in the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after purchasing an additional 119,909 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its stake in shares of Gilead Sciences by 72.6% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 4,487 shares of the biopharmaceutical company’s stock valued at $308,000 after acquiring an additional 1,887 shares during the last quarter. Mather Group LLC. lifted its stake in shares of Gilead Sciences by 24.1% in the 2nd quarter. Mather Group LLC. now owns 13,157 shares of the biopharmaceutical company’s stock valued at $964,000 after acquiring an additional 2,556 shares during the last quarter. Kingswood Wealth Advisors LLC grew its position in Gilead Sciences by 90.6% during the 2nd quarter. Kingswood Wealth Advisors LLC now owns 21,906 shares of the biopharmaceutical company’s stock worth $1,503,000 after acquiring an additional 10,412 shares during the last quarter. Finally, CWM LLC increased its stake in Gilead Sciences by 4.4% in the 2nd quarter. CWM LLC now owns 391,832 shares of the biopharmaceutical company’s stock worth $26,884,000 after purchasing an additional 16,616 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.2 %

Shares of GILD stock opened at $92.58 on Monday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The stock has a market cap of $115.38 billion, a P/E ratio of 1,028.67, a P/E/G ratio of 2.87 and a beta of 0.17. The stock has a 50 day moving average of $88.26 and a 200 day moving average of $77.84. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.29 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 4.37 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.33%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 227,946 shares of company stock worth $20,683,305. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent analyst reports. UBS Group raised their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Barclays boosted their price target on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Cantor Fitzgerald lifted their price objective on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Citigroup started coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target for the company. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $95.41.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.